title: High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
abstract: BACKGROUND
  The aim of this study was to evaluate an alternative treatment (consensus interferon plus ribavirin) for chronic hepatitis C patients resistant to combined therapy.
  
  
  METHODS
  Fourteen patients previously resistant to interferon alpha plus ribavirin were consecutively assigned to receive 15 microg of consensus interferon plus ribavirin (1000 mg) daily for 4 weeks, and 9-15 microg every other day plus daily ribavirin for the following 44 weeks. Alanine aminotransferase and hepatitis C virus (HCV) RNA (Amplicor Monitor; Roche) levels were monitored during therapy and for 24 weeks after its completion.
  
  
  RESULTS
  A rapid and marked decrease of HCV RNA viremia of more than 2 logs was observed in 10 (71%) of 14 patients at week 2 of treatment. At the end of therapy, 10 (71%) of 14 patients had undetectable HCV RNA. The end-of-treatment response rates were 6 of 9 (67%) patients for genotype 1 and 4 of 5 (80%) for other genotypes. Sustained response was observed in 4 (36%) of 11 patients who completed 24 weeks of follow-up.
  
  
  CONCLUSIONS
  A marked and rapid decrease of viral load was observed during therapy with high doses of consensus interferon plus ribavirin in patients previously resistant to combined therapy, even in those infected with genotype 1. Of 11 patients who completed the post-treatment follow-up, 36% presented a sustained response.
authors.affiliation: Institute of Tropical Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil.
authors.forename: Luiz Caetano
authors.initials: LC
authors.lastname: da Silva
authors.forename: Leda
authors.initials: L
authors.lastname: Bassit
authors.forename: Suzane Kioko
authors.initials: SK
authors.lastname: Ono-Nita
authors.forename: João Renato Rebello
authors.initials: JR
authors.lastname: Pinho
authors.forename: Ana
authors.initials: A
authors.lastname: Nishiya
authors.forename: Carmen Lucia
authors.initials: CL
authors.lastname: Madruga
authors.forename: Flair José
authors.initials: FJ
authors.lastname: Carrilho
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; C050739:interferon alfacon-1; D000410:Alanine Transaminase